CHIRON |
Science For Life™
Background: rFGF-2
•Preclinical Studies
–angiogenic agent in multiple
ischemia models
•Clinical Trials with rFGF-2
–Chiron Phase I CAD study: defined MTD
–Chiron Phase II CAD study
–NIH-NHLBI Phase I PAD & CAD
•